Pfizer fuels Cartography push

The private US biotech Cartography has raised $67 million in a series B financing, led primarily by Pfizer Ventures, to push an approach with which Roche recently failed. The company's lead asset, CBI-1214, is a T-cell engager that targets LY6G6D, a selectively expressed colorectal cancer antigen with a high prevalence in microsatellite-stable colorectal cancer. This target has been gaining momentum, with several programmes presented at this year’s AACR. However, the first-in-human data presented by Roche during that congress with a T-cell engager called linclatamig were underwhelming; among 46 metastatic colorectal cancer patients, 74% had skin-related toxicities indicating possible on-target/off-tumour effects, while clinical activity was limited, with only one confirmed partial response. Cartography argues that CBI-1214 is designed to optimise antitumor activity, and plans to submit an IND by the year-end. Beyond this project, its pipeline also includes another T-cell engager, in addition to other preclinical assets.

LY6G6D-targeting T-cell engagers

Source: OncologyPipeline